Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 175.56% | 47.50% | -192.25% | 70.53% | 57.12% |
| Total Depreciation and Amortization | 0.00% | -9.36% | -6.97% | -3.64% | -1.65% |
| Total Amortization of Deferred Charges | -20.42% | 161.81% | 2.86% | -14.11% | 123.29% |
| Total Other Non-Cash Items | -32.86% | -58.63% | 150.02% | -25.44% | -40.01% |
| Change in Net Operating Assets | -531.19% | 224.31% | 66.09% | -220.11% | -1.50% |
| Cash from Operations | -449.45% | 173.22% | 51.62% | -487.62% | 126.75% |
| Capital Expenditure | -48.03% | 32.34% | -- | -- | 68.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 173.32% | 63.91% | 110.09% | 114.86% | 61.66% |
| Cash from Investing | 187.61% | 93.85% | 60.25% | 114.46% | 61.95% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,921.43% | -97.22% | -- | -- | -99.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -200.00% | 650.00% | 99.35% |
| Cash from Financing | 2,921.43% | -97.15% | 4,372.73% | -94.47% | -99.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.17% | 456.35% | 74.91% | -33.08% | -128.89% |
